Literature DB >> 1614537

Amplification of a gene encoding a p53-associated protein in human sarcomas.

J D Oliner1, K W Kinzler, P S Meltzer, D L George, B Vogelstein.   

Abstract

Despite extensive data linking mutations in the p53 gene to human tumorigenesis, little is known about the cellular regulators and mediators of p53 function. MDM2 is a strong candidate for one such cellular protein; the MDM2 gene was originally identified by virtue of its amplification in a spontaneously transformed derivative of mouse BALB/c cells and the MDM2 protein subsequently shown to bind to p53 in rat cells transfected with p53 genes. To determine whether MDM2 plays a role in human cancer, we have cloned the human MDM2 gene. Here we show that recombinant-derived human MDM2 protein binds human p53 in vitro, and we use MDM2 clones to localize the human MDM2 gene to chromosome 12q13-14. Because this chromosomal position appears to be altered in many sarcomas, we looked for changes in human MDM2 in such cancers. The gene was amplified in over a third of 47 sarcomas, including common bone and soft tissue forms. These results are consistent with the hypothesis that MDM2 binds to p53, and that amplification of MDM2 in sarcomas leads to escape from p53-regulated growth control. This mechanism of tumorigenesis parallels that for virally-induced tumours, in which viral oncogene products bind to and functionally inactivate p53.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1614537     DOI: 10.1038/358080a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  535 in total

Review 1.  Soft tissue sarcomas and p53 mutations.

Authors:  H Taubert; A Meye; P Würl
Journal:  Mol Med       Date:  1998-06       Impact factor: 6.354

2.  pRB induces Sp1 activity by relieving inhibition mediated by MDM2.

Authors:  T Johnson-Pais; C Degnin; M J Thayer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 3.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

4.  MDM2 suppresses p73 function without promoting p73 degradation.

Authors:  X Zeng; L Chen; C A Jost; R Maya; D Keller; X Wang; W G Kaelin; M Oren; J Chen; H Lu
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

5.  Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Authors:  M S Rodriguez; J M Desterro; S Lain; D P Lane; R T Hay
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

6.  Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer.

Authors:  R Ralhan; A Sandhya; M Meera; W Bohdan; S K Nootan
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

7.  Regions and activities of simian virus 40 T antigen that cooperate with an activated ras oncogene in transforming primary rat embryo fibroblasts.

Authors:  Tina M Beachy; Sara L Cole; Jane F Cavender; Mary J Tevethia
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon.

Authors:  N Vlatkovic; S Guerrera; Y Li; S Linn; D S Haines; M T Boyd
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

9.  Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma.

Authors:  A Pandita; M Zielenska; P Thorner; J Bayani; R Godbout; M Greenberg; J A Squire
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

10.  Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response.

Authors:  Alex Lyakhovich; Malathy P V Shekhar
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.